{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:13Z","timestamp":1793316553769,"version":"4.5.0"},"reference-count":62,"publisher":"American Association for Cancer Research (AACR)","issue":"24","funder":[{"DOI":"10.13039\/100015581","name":"Houston Methodist Research Institute","doi-asserted-by":"publisher","award":["Emily Herman Endowed Chair Fund"],"award-info":[{"award-number":["Emily Herman Endowed Chair Fund"]}],"id":[{"id":"10.13039\/100015581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015581","name":"Houston Methodist Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Identifying novel cell surface receptors that regulate leukemia cell differentiation and can be targeted to inhibit cellular proliferation is crucial to improve current treatment modalities in acute myeloid leukemia (AML), especially for relapsed or chemotherapy-refractory leukemia. Leukocyte immunoglobulin-like receptor type B (LILRB) is an immunomodulatory receptor originally found to be expressed in myeloid cells. In this study, we found that LILRB receptors can be induced under inflammatory stimuli and chemotherapy treatment conditions. Blockade of LILRB3 inhibited leukemia cell proliferation and leukemia progression. In addition, treatment with LILRB3 blocking antibodies upregulated myeloid lineage differentiation transcription factors, including PU.1, C\/EBP family, and IRF, whereas phosphorylation of proliferation regulators, for example, AKT, cyclin D1, and retinoblastoma protein, was decreased. Conversely, transcriptomic analysis showed LILRB3 activation by agonist antibodies may enhance leukemia survival through upregulation of cholesterol metabolism, which has been shown to promote leukemia cell survival. Moreover, LILRB3-targeted CAR T cells exhibited potent antitumor effects both in vitro and in vivo. Taken together, our results suggest that LILRB3 is a potentially potent target for multiple treatment modalities in AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>LILRB3 regulates differentiation and proliferation in acute myeloid leukemia and can be targeted with monoclonal antibodies and CAR T cells to suppress leukemia growth.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-22-2483","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T03:13:18Z","timestamp":1702609998000},"page":"4047-4062","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy"],"prefix":"10.1158","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6782-7331","authenticated-orcid":false,"given":"Sunny","family":"Mai","sequence":"first","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-8049","authenticated-orcid":false,"given":"Alan","family":"Hodges","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."},{"name":"2Texas A&M University System School of Medicine, Bryan, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1162-1411","authenticated-orcid":false,"given":"Hui-Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9756-6526","authenticated-orcid":false,"given":"Jilu","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7243-6221","authenticated-orcid":false,"given":"Yi-Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5211-4278","authenticated-orcid":false,"given":"Yongbin","family":"Liu","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4290-7578","authenticated-orcid":false,"given":"Fumiko","family":"Nakatsu","sequence":"additional","affiliation":[{"name":"3Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4159-6387","authenticated-orcid":false,"given":"Xiaoxuan","family":"Wang","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3656-5668","authenticated-orcid":false,"given":"Jing","family":"Fang","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0558-3749","authenticated-orcid":false,"given":"Yitian","family":"Xu","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2449-6165","authenticated-orcid":false,"given":"Vitaliy","family":"Davidov","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."},{"name":"2Texas A&M University System School of Medicine, Bryan, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4465-0617","authenticated-orcid":false,"given":"Kyeongah","family":"Kang","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-8746","authenticated-orcid":false,"given":"Sai Ravi","family":"Pingali","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."},{"name":"4Division of Hematology, Medical Oncology and Hematology, Houston Methodist Hospital, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-762X","authenticated-orcid":false,"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."},{"name":"4Division of Hematology, Medical Oncology and Hematology, Houston Methodist Hospital, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-4199","authenticated-orcid":false,"given":"Masataka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"5Center for Gene Therapy, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"6Department of Oncology, Albert Einstein College of Medicine, Bronx, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-0774","authenticated-orcid":false,"given":"Brooke","family":"Prinzing","sequence":"additional","affiliation":[{"name":"7Department of Bone Marrow Transplantation & Cellular Therapy, St Jude Children's Research Hospital, Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8574-9974","authenticated-orcid":false,"given":"Youli","family":"Zu","sequence":"additional","affiliation":[{"name":"8Department of Pathology & Genomic Medicine, Houston Methodist Research Institute, Houston Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-7468","authenticated-orcid":false,"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[{"name":"7Department of Bone Marrow Transplantation & Cellular Therapy, St Jude Children's Research Hospital, Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0077-0040","authenticated-orcid":false,"given":"Yong","family":"Lu","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-5775","authenticated-orcid":false,"given":"Shu-Hsia","family":"Chen","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."},{"name":"2Texas A&M University System School of Medicine, Bryan, Texas."},{"name":"9Department of Physiology, Biophysics, and Systems Biology, Weill Cornell Medical Science and Graduate School of Medical Sciences, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2971-4221","authenticated-orcid":false,"given":"Ping-Ying","family":"Pan","sequence":"additional","affiliation":[{"name":"1Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas."},{"name":"2Texas A&M University System School of Medicine, Bryan, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"2025121108373504800_bib1","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-20-3187","article-title":"AACR cancer progress report 2020: turning science into lifesaving care","volume":"26","author":"Sengupta","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025121108373504800_bib2","article-title":"Robbins & Cotran pathologic basis of disease","author":"Kumar","year":"2020"},{"key":"2025121108373504800_bib3","volume-title":"Prognosis of acute myeloid leukemia","author":"Schiffer"},{"key":"2025121108373504800_bib4","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"2025121108373504800_bib5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjh.12425","article-title":"Survival and cure of acute myeloid leukaemia in England, 1971\u20132006: a population-based study","volume":"162","author":"Shah","year":"2013","journal-title":"Br J Haematol"},{"key":"2025121108373504800_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"2025121108373504800_bib7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T cells for acute myeloid leukemia: state of the art and future directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front Oncol"},{"key":"2025121108373504800_bib8","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1172\/JCI97570","article-title":"Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity","volume":"128","author":"Chen","year":"2018","journal-title":"J Clin Invest"},{"key":"2025121108373504800_bib9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-017-2023-x","article-title":"LILRB receptor-mediated regulation of myeloid cell maturation and function","volume":"66","author":"van der Touw","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"2025121108373504800_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/ni0302-215","article-title":"T(S) cells and immune tolerance induction: a regulatory renaissance?","volume":"3","author":"Feinberg","year":"2002","journal-title":"Nat Immunol"},{"key":"2025121108373504800_bib11","doi-asserted-by":"crossref","first-page":"34839","DOI":"10.1074\/jbc.M109.035683","article-title":"Leukocyte Ig-like receptor B4 (LILRB4) is a potent inhibitor of FcgammaRI-mediated monocyte activation via dephosphorylation of multiple kinases","volume":"284","author":"Lu","year":"2009","journal-title":"J Biol Chem"},{"key":"2025121108373504800_bib12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature11095","article-title":"Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development","volume":"485","author":"Zheng","year":"2012","journal-title":"Nature"},{"key":"2025121108373504800_bib13","doi-asserted-by":"crossref","first-page":"eaan2507","DOI":"10.1126\/science.aan2507","article-title":"A pathology atlas of the human cancer transcriptome","volume":"357","author":"Uhlen","year":"2017","journal-title":"Science"},{"key":"2025121108373504800_bib14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/sj.leu.2402835","article-title":"Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia","volume":"17","author":"Panoskaltsis","year":"2003","journal-title":"Leukemia"},{"key":"2025121108373504800_bib15","first-page":"7","article-title":"Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia","volume":"36","author":"Park","year":"2006","journal-title":"Ann Clin Lab Sci"},{"key":"2025121108373504800_bib16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00262-006-0236-5","article-title":"T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005","volume":"56","author":"Ersvaer","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"2025121108373504800_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00262-006-0159-1","article-title":"Effects of interferon gamma on native human acute myelogenous leukaemia cells","volume":"56","author":"Ersvaer","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"2025121108373504800_bib18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/bmt.2008.380","article-title":"HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94\/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT","volume":"43","author":"Nguyen","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2025121108373504800_bib19","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00262-010-0909-y","article-title":"In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors","volume":"59","author":"Berthon","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"2025121108373504800_bib20","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-21-3594","article-title":"Release of IFN-gamma by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells","volume":"28","author":"Corradi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025121108373504800_bib21","first-page":"52","article-title":"Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon","volume":"1","author":"Beran","year":"1987","journal-title":"Leukemia"},{"key":"2025121108373504800_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.omtm.2018.01.009","article-title":"Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma","volume":"9","author":"Yi","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025121108373504800_bib23","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s43018-021-00262-0","article-title":"LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2\u2013cFLIP\u2013NF-\u03baB signaling axis","volume":"2","author":"Wu","year":"2021","journal-title":"Nature Cancer"},{"key":"2025121108373504800_bib24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2025121108373504800_bib25","doi-asserted-by":"crossref","first-page":"D917","DOI":"10.1093\/nar\/gkv1101","article-title":"BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis","volume":"44","author":"Bagger","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2025121108373504800_bib26","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.2022016033","article-title":"Proteomic and phosphoproteomic landscapes of acute myeloid leukemia","volume":"140","author":"Kramer","year":"2022","journal-title":"Blood"},{"key":"2025121108373504800_bib27","doi-asserted-by":"crossref","first-page":"eaaz0463","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025121108373504800_bib28","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","article-title":"Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia","volume":"32","author":"Petrov","year":"2018","journal-title":"Leukemia"},{"key":"2025121108373504800_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/ijc.2910170504","article-title":"Establishment and characterization of a human histiocytic lymphoma cell line (U-937)","volume":"17","author":"Sundstrom","year":"1976","journal-title":"Int J Cancer"},{"key":"2025121108373504800_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/288095a0","article-title":"Heterogeneity of poly(I) x poly(C)-induced human fibroblast interferon mRNA species","volume":"288","author":"Sehgal","year":"1980","journal-title":"Nature"},{"key":"2025121108373504800_bib31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0022-1759(89)90236-6","article-title":"The production of polyclonal and monoclonal antibodies in mice using novel immunization methods","volume":"120","author":"Hong","year":"1989","journal-title":"J Immunol Methods"},{"key":"2025121108373504800_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.stem.2008.11.015","article-title":"Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells","volume":"4","author":"Somervaille","year":"2009","journal-title":"Cell stem cell"},{"key":"2025121108373504800_bib33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the cancer cell line encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"2025121108373504800_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fimmu.2017.00092","article-title":"Regulation of epigenetic modifiers, including KDM6B, by interferon-gamma and interleukin-4 in human macrophages","volume":"8","author":"Yildirim-Buharalioglu","year":"2017","journal-title":"Front Immunol"},{"key":"2025121108373504800_bib35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025121108373504800_bib36","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"2025121108373504800_bib37","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.2013.32","article-title":"Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer","volume":"108","author":"Ino","year":"2013","journal-title":"Br J Cancer"},{"key":"2025121108373504800_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.immuni.2011.02.004","article-title":"Paired immunoglobin-like receptor-b regulates the suppressive function and fate of myeloid-derived suppressor cells","volume":"34","author":"Ma","year":"2011","journal-title":"Immunity"},{"key":"2025121108373504800_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/leu.2014.162","article-title":"Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling","volume":"29","author":"Sharma","year":"2015","journal-title":"Leukemia"},{"key":"2025121108373504800_bib40","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1182\/blood-2002-06-1677","article-title":"Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations","volume":"101","author":"Mizuki","year":"2003","journal-title":"Blood"},{"key":"2025121108373504800_bib41","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V126.23.305.305","article-title":"Minimal reduction of PU.1 is sufficient to induce a preleukemic state and promote development of acute myeloid leukemia","volume":"126","author":"Will","year":"2015","journal-title":"Blood"},{"key":"2025121108373504800_bib42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nri2024","article-title":"Transcription factors in myeloid development: balancing differentiation with transformation","volume":"7","author":"Rosenbauer","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"2025121108373504800_bib43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/leu.2012.258","article-title":"C\/EBPbeta promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion","volume":"27","author":"Hayashi","year":"2013","journal-title":"Leukemia"},{"key":"2025121108373504800_bib44","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1093\/emboj\/cdg556","article-title":"C\/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells","volume":"22","author":"Duprez","year":"2003","journal-title":"EMBO J"},{"key":"2025121108373504800_bib45","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2005-07-3068","article-title":"ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression","volume":"107","author":"Mueller","year":"2006","journal-title":"Blood"},{"key":"2025121108373504800_bib46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2443.2003.00620.x","article-title":"Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway","volume":"8","author":"Iwasa","year":"2003","journal-title":"Genes Cells"},{"key":"2025121108373504800_bib47","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/emboj.2011.69","article-title":"p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype","volume":"30","author":"Freund","year":"2011","journal-title":"EMBO J"},{"key":"2025121108373504800_bib48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1091\/mbc.8.2.287","article-title":"Cyclin D1\/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation","volume":"8","author":"Connell-Crowley","year":"1997","journal-title":"Mol Biol Cell"},{"key":"2025121108373504800_bib49","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1101\/gad.813200","article-title":"The Rb\/E2F pathway: expanding roles and emerging paradigms","volume":"14","author":"Harbour","year":"2000","journal-title":"Genes Dev"},{"key":"2025121108373504800_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","article-title":"The RB and p53 pathways in cancer","volume":"2","author":"Sherr","year":"2002","journal-title":"Cancer Cell"},{"key":"2025121108373504800_bib51","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/excr.1998.4007","article-title":"Hypophosphorylation of the RB protein in S and G2 as well as G1 during growth arrest","volume":"241","author":"Yen","year":"1998","journal-title":"Exp Cell Res"},{"key":"2025121108373504800_bib52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2009-02-205153","article-title":"Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin","volume":"114","author":"Assouline","year":"2009","journal-title":"Blood"},{"key":"2025121108373504800_bib53","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.3390\/cancers14153567","article-title":"Proteomic profiling identifies specific leukemic stem cell-associated protein expression patterns in pediatric AML patients","volume":"14","author":"Petersen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025121108373504800_bib54","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","article-title":"Antileukemic activity of rapamycin in acute myeloid leukemia","volume":"105","author":"Recher","year":"2005","journal-title":"Blood"},{"key":"2025121108373504800_bib55","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.stem.2012.06.009","article-title":"mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis","volume":"11","author":"Kalaitzidis","year":"2012","journal-title":"Cell stem cell"},{"key":"2025121108373504800_bib56","doi-asserted-by":"crossref","first-page":"e105381","DOI":"10.1371\/journal.pone.0105381","article-title":"Inhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiation","volume":"9","author":"Pan","year":"2014","journal-title":"PLoS One"},{"key":"2025121108373504800_bib57","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/1947601911416357","article-title":"Critical role of c-Myc in acute myeloid leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2","volume":"2","author":"Salvatori","year":"2011","journal-title":"Genes Cancer"},{"key":"2025121108373504800_bib58","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2004-01-0395","article-title":"Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells","volume":"104","author":"Banker","year":"2004","journal-title":"Blood"},{"key":"2025121108373504800_bib59","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood.V52.6.1099.1099","article-title":"Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells","volume":"52","author":"Ho","year":"1978","journal-title":"Blood"},{"key":"2025121108373504800_bib60","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2002-07-2283","article-title":"Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses","volume":"101","author":"Li","year":"2003","journal-title":"Blood"},{"key":"2025121108373504800_bib61","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFNgamma reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2025121108373504800_bib62","doi-asserted-by":"crossref","first-page":"7599","DOI":"10.1158\/1078-0432.CCR-04-0598","article-title":"CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes","volume":"10","author":"Suarez","year":"2004","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/24\/4047\/3391037\/4047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/24\/4047\/3391037\/4047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:37:52Z","timestamp":1765460272000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/83\/24\/4047\/731562\/LILRB3-Modulates-Acute-Myeloid-Leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":62,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12,15]]},"published-print":{"date-parts":[[2023,12,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-22-2483","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.24825807.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825798.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825804.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704815","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704827","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30833931","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825189","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825192.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825801.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825801","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825813","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30833946","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825807","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704812","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825195","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825813.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704818","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825195.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30833940","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825798","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30833934","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32704821","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825804","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30833937","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825186.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825189.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825192","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24825186","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6982719.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6982719","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]}}}